Elicio Therapeutics to Present Cancer Trial Results
The company will unveil Phase 2 data at the SITC Annual Meeting in Phoenix this November.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Do you believe current cancer vaccine research is likely to produce successful treatments for patients?
Elicio Therapeutics is set to share clinical results from its Phase 2 AMPLIFY-7P trial during the SITC Annual Meeting occurring November 4-8, 2026, in Phoenix. The presentation will highlight the study's evaluation of camupepimut for patients with mutant KRAS-driven pancreatic cancer.
Why it matters
The study aims to determine the efficacy of targeting KRAS mutations in pancreatic ductal adenocarcinoma, a major challenge in oncology. These results represent a significant update for the biotechnology sector regarding potential new immunotherapy approaches.
The AMPLIFY-7P study enrolled 144 patients across 24 U.S. clinical sites to test camupepimut, which targets seven distinct KRAS mutations. Data indicates that KRAS mutations are present in approximately 25% of all solid tumor cases.
The players
Elicio Therapeutics
This clinical-stage biotechnology company specializes in developing immunotherapies that target cancer via the lymph nodes.
The details
Camupepimut utilizes the company's proprietary Amphiphile technology to deliver peptide antigens and an adjuvant directly to the lymph nodes. Researchers also plan to display preclinical findings regarding the broader AMP-platform, which employs an antigen-agnostic approach to intratumoral treatment.
Timeline
The SITC Annual Meeting takes place in Phoenix from November 4 to 8, 2026.
The company will deliver a keynote presentation on the study results on November 6, 2026.
Two additional poster presentations of clinical and preclinical data are scheduled for November 7, 2026.
The Big Picture
The presentation of the AMPLIFY-7P trial results extends the development trajectory of the AMP-platform as Elicio moves toward clinical validation.
Patients currently managing KRAS-mutant pancreatic cancer may see new treatment options emerge if the Phase 2 trial successfully demonstrates efficacy. These advancements could potentially shift standard care protocols for those with these specific tumor mutations.
The takeaway
Clinical trials focused on KRAS mutations represent a vital step forward in treating difficult solid tumors. Participants and their families should discuss potential trial eligibility with their oncology teams as new data becomes available.
Further reading
Learn more about the latest research and clinical developments in our Cancer section.
More information
Review the latest corporate updates and research documentation on the Elicio Therapeutics official company website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe current cancer vaccine research is likely to produce successful treatments for patients?
